For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
In the latest session, Takeda Pharmaceutical Co ADR (NYSE: TAK) closed at $14.99 up 0.13% from its previous closing price of $14.97. In other words, the price has increased by $0.13 from its previous closing price. On the day, 1.74 million shares were traded. TAK stock price reached its highest trading level at $15.01 during the session, while it also had its lowest trading level at $14.905.
Ratios:
For a deeper understanding of Takeda Pharmaceutical Co ADR’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 19.33 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 8.66. For the most recent quarter (mrq), Quick Ratio is recorded 0.59 and its Current Ratio is at 1.16. In the meantime, Its Debt-to-Equity ratio is 0.66 whereas as Long-Term Debt/Eq ratio is at 0.60.
On March 16, 2023, BofA Securities Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $20. Cowen Upgraded its Market Perform to Outperform on July 19, 2022, whereas the target price for the stock was revised from $21 to $24.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jul 09 ’25 when Thomas Wozniewski bought 6,136 shares for $15.42 per share.
Teresa Marie Bitetti bought 52,649 shares of TAK for $811,848 on Jul 09 ’25. On Jul 09 ’25, another insider, Ramona A Sequeira, who serves as the President, Global Portfolio Di of the company, bought 102,972 shares for $15.42 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TAK now has a Market Capitalization of 47550976000 and an Enterprise Value of 4715434213376. As of this moment, Takeda’s Price-to-Earnings (P/E) ratio for their current fiscal year is 50.69, and their Forward P/E ratio for the next fiscal year is 23.08. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.13. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.56 while its Price-to-Book (P/B) ratio in mrq is 0.99. Its current Enterprise Value per Revenue stands at 1.052 whereas that against EBITDA is 3.868.
Stock Price History:
The Beta on a monthly basis for TAK is 0.26, which has changed by 0.00469172 over the last 52 weeks, in comparison to a change of 0.16844666 over the same period for the S&P500. Over the past 52 weeks, TAK has reached a high of $15.56, while it has fallen to a 52-week low of $12.80. The 50-Day Moving Average of the stock is 1.38%, while the 200-Day Moving Average is calculated to be 4.76%.
Shares Statistics:
For the past three months, TAK has traded an average of 3.42M shares per day and 2797280 over the past ten days. A total of 3.12B shares are outstanding, with a floating share count of 3.12B. Insiders hold about 0.00% of the company’s shares, while institutions hold 2.51% stake in the company. Shares short for TAK as of 1755216000 were 8172033 with a Short Ratio of 2.39, compared to 1752537600 on 4533397. Therefore, it implies a Short% of Shares Outstanding of 8172033 and a Short% of Float of 0.26.
Dividends & Splits
According to the company, the forward annual dividend rate for TAK is 0.33, from 196.0 in the trailing year. Against a Trailing Annual Dividend Yield of 13.092853The stock’s 5-year Average Dividend Yield is 4.69.
Earnings Estimates
Analysts are recommending an EPS of between $74.07 and $74.07 for the fiscal current year, implying an average EPS of $74.07. EPS for the following year is $197.75, with 2.0 analysts recommending between $273.16 and $122.33.
Revenue Estimates
A total of 5 analysts believe the company’s revenue will be $1.19T this quarter.It ranges from a high estimate of $1.25T to a low estimate of $1.13T. As of the current estimate, Takeda Pharmaceutical Co ADR’s year-ago sales were $1.18TFor the next quarter, 5 analysts are estimating revenue of $1.18T. There is a high estimate of $1.24T for the next quarter, whereas the lowest estimate is $1.13T.
A total of 14 analysts have provided revenue estimates for TAK’s current fiscal year. The highest revenue estimate was $4.68T, while the lowest revenue estimate was $4.35T, resulting in an average revenue estimate of $4.55T. In the same quarter a year ago, actual revenue was $580.36BBased on 14 analysts’ estimates, the company’s revenue will be $4.59T in the next fiscal year. The high estimate is $4.73T and the low estimate is $4.33T.
